Search Result
Results for "
Leukotriene receptors
" in MedChemExpress (MCE) Product Catalog:
7
Isotope-Labeled Compounds
Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-118958
-
Ro 23-3544
|
Leukotriene Receptor
|
Inflammation/Immunology
|
Ablukast (Ro 23-3544) is a specific and active leukotriene receptor antagonist. Ablukast effectively reduces LTC4- and antigen-induced bronchoconstriction . Ablukast is LTD4 receptor antagonist .
|
-
-
- HY-147086
-
|
Leukotriene Receptor
G protein-coupled Bile Acid Receptor 1
TNF Receptor
|
Metabolic Disease
Inflammation/Immunology
|
CAY10789 (compound 6) is a potent CysLT1R (cysteinyl leukotriene receptor 1) antagonist (IC50=2.80 μM) and GPBAR1 (G-protein-coupled bile acid receptor 1) agonist (EC50=3 μM). CAY10789 significantly reduces the adhesion of U937 cells to HAEC, reduces the expression of TNF-α. CAY10789 shows very promising metabolic stability and excellent pharmacokinetics. CAY10789 can be used for the research of colitis, metabolic syndromes, and other GPBAR1/CysLT1R-related diseases .
|
-
-
- HY-112736
-
-
-
- HY-119442
-
|
Leukotriene Receptor
|
Cardiovascular Disease
|
Quininib is a cysteinyl leukotriene 1 and 2 receptor antagonist with IC50s of 1.2 and 52 μM for CysLT1R and CysLT2R, respectively. Quininib is a potent inhibitor of developmental angiogenesis in the zebrafish eye. Quininib can be used for the research of ocular neovascular pathologies and may complement current anti-VEGF biological agents .
|
-
-
- HY-122124
-
|
Leukotriene Receptor
|
Inflammation/Immunology
|
CAY10583 is a potent and selective full Leukotriene B4 receptor type 2 (BLT2) agonist. CAY10583 directly promotes keratinocyte migration in vitro and accelerates wound closure in vivo. CAY10583 is a promising pharmaceutical agent for diabetic wounds .
|
-
-
- HY-131651
-
LTB4 ethanolamide
|
Endogenous Metabolite
Leukotriene Receptor
|
Cancer
|
Leukotriene B4 ethanolamide (LTB4 ethanolamide) is an antagonist and a partial agonist for Leukotriene B4 (LTB4) receptor 1 (BLTR1). Leukotriene B4 ethanolamide ameliorates the tumor progression, which is only asscociated with inflammation .
|
-
-
- HY-113483
-
20-COOH LTB4
|
Drug Metabolite
Leukotriene Receptor
|
Metabolic Disease
|
20-Carboxy-Leukotriene B4 (20-COOH LTB4) is a metabolite of Leukotriene B4 (LTB4; HY-107608). 20-Carboxy-Leukotriene B4 binds to the BLT1 receptor with high affinity. 20-Carboxy-Leukotriene B4 inhibits LTB4-mediated neutrophil responses (migration, degranulation, leukotriene biosynthesis) .
|
-
-
- HY-U00253
-
-
-
- HY-U00263
-
-
-
- HY-U00252
-
-
-
- HY-19193
-
-
-
- HY-112532
-
|
Leukotriene Receptor
Lipoxygenase
|
Inflammation/Immunology
|
REV 5901 is a competitive and orally active antagonist of leukotriene receptor, with a Ki of 0.7 μM. REV 5901 is also a 5-lipoxygenase inhibitor. REV 5901 can be used for the research of asthma in which leukotriene release be involved .
|
-
-
- HY-105221
-
-
-
- HY-76511
-
-
-
- HY-107607
-
|
Leukotriene Receptor
|
Inflammation/Immunology
|
FPL-55712 free base is a leukotriene receptor antagonist. FPL-55712 free base is also an antagonist of slow reacting substance of anaphylaxis (SRS-A). FPL-55712 free base inhibits leukotriene-induced bronchoconstriction .
|
-
-
- HY-14938
-
KCA 757; MN 001
|
Leukotriene Receptor
|
Inflammation/Immunology
|
Tipelukast (KCA 757) is a sulfidopeptide leukotriene receptor antagonist, an orally bioavailable anti-inflammatory agent and used for the treatment of asthma.
|
-
-
- HY-112737
-
-
-
- HY-112248
-
-
-
- HY-108396
-
-
-
- HY-117557
-
-
-
- HY-W747565
-
LTB4-APA
|
Leukotriene Receptor
|
Inflammation/Immunology
|
Leukotriene B4-3-aminopropylamide (LTB4-APA) is a leukotriene immunomodulator. The study found that LTB4 can bind to the polar carboxylic acid group of LTB4 near the outer surface of BLT1 cells, and the hydrophobic LTB4 tail points to the transmembrane region of the receptor protein .
|
-
-
- HY-107609
-
|
Leukotriene Receptor
|
Inflammation/Immunology
|
BAY-u 9773 is a non-selective antagonist of the CysLT receptors (cysteinyl leukotrienes receptors) with about the same IC50 for CysLT 1 and CysLT 2. BAY-u9773 is used for the inhibition of LT responses .
|
-
-
- HY-U00072
-
-
-
- HY-112650
-
-
-
- HY-17492
-
-
-
- HY-76511S
-
MK-679-d6; L 668019-d6
|
Leukotriene Receptor
|
Inflammation/Immunology
|
Verlukast-d6 is a deuterium labeled Verlukast. Verlukast is a potent, selective, and orally active antagonist of leukotriene receptor. Verlukast has the potential for the research of asthma[1].
|
-
-
- HY-108162A
-
|
COX
|
Inflammation/Immunology
|
Ataquimast is a COX-2 inhibitor that inhibits the release of leukotrienes, TNF-α and GM-CSF. Ataquimast can be used in the study of advanced receptor-positive breast cancer .
|
-
-
- HY-100316
-
-
-
- HY-117706
-
|
Leukotriene Receptor
|
Inflammation/Immunology
|
LY 292728 is a potent leukotriene B4 (LTB4) receptor antagonist. LY 292728 binds to human neutrophils with a Ki of 0.47 nM and binds to guinea pig lung membranes with a Ki of 0.04 nM .
|
-
-
- HY-101731
-
|
Leukotriene Receptor
|
Inflammation/Immunology
|
CP-96021 hydrochloride is a balanced, combined, potent and orally active leukotriene D4 (LTD4)/platelet activating factor (PAF) receptor antagonist with Ki values of 34 nM and 37 nM, respectively .
|
-
-
- HY-108162
-
|
COX
|
Inflammation/Immunology
|
Ataquimast free base is a COX-2 inhibitor that inhibits the release of leukotrienes, TNF-α and GM-CSF. Ataquimast free base can be used in the study of advanced receptor-positive breast cancer .
|
-
-
- HY-149083
-
|
Leukotriene Receptor
|
Inflammation/Immunology
|
LTB4 antagonist 2, a carboxamide-acid compound, is an antagonist of leukotriene B4 (LTB4) with potentially anti-inflammatory activity. LTB4 antagonist 2 shows good affinity for the LTB4 receptor with IC50 of 439 nM .
|
-
-
- HY-114641A
-
|
Leukotriene Receptor
|
Inflammation/Immunology
|
BIIL-260 hydrochloride is a potent and long-acting orally active leukotriene B(4) receptor LTB4 antagonist, with anti-inflammatory activity. BIIL-260 hydrochloride interacts with the LTB4 receptor in a saturable, reversible, and competitive manner, has high affinity to the LTB4 receptor on isolated human neutrophil cell membranes with Ki values of 1.7 nM .
|
-
-
- HY-17492S
-
-
-
- HY-17492S3
-
-
-
- HY-17492R
-
|
Leukotriene Receptor
|
Inflammation/Immunology
Cancer
|
Zafirlukast (Standard) is the analytical standard of Zafirlukast. This product is intended for research and analytical applications. Zafirlukast (ICI 204219) is a potent orally active leukotriene D4 (LTD4) receptor antagonist. Zafirlukast shows anti-asthmatic, anti-inflammatory and anti-bacterial effects.
|
-
-
- HY-17492S1
-
-
-
- HY-17492S2
-
-
-
- HY-156978
-
Wy-48252
|
Leukotriene Receptor
|
Others
|
Ritolukast (Wy-48252) is an orally active aerosol leukotriene (LTD4/E4) receptor antagonist. Ritolukast can be used to inhibit the bronchoconstriction caused by aerosol LTD4 in guinea pigs, with an ID50 of 0.5mg/kg .
|
-
-
- HY-130138A
-
|
Others
|
Inflammation/Immunology
|
(5S,6R)-DiHETE is an enantiomer of (5,6)-DiHETEs. (5S,6R)-DiHETE can be recognized by leukotriene receptors (LTD4 receptors). (5S,6R)-DiHETE can induce guinea pig isolated ileum contraction? with an EC50 of 1.3 μM, and this effect can be inhibited by LTD4 receptor antagonists .
|
-
-
- HY-13315S1
-
MK0476-d6
|
Leukotriene Receptor
|
Inflammation/Immunology
|
Montelukast-d6 (sodium) is the deuterium labeled Montelukast (sodium). Montelukast sodium is a potent, selective and orally active antagonist of cysteinyl leukotriene receptor 1 (Cysltr1). Montelukast sodium can be used for the reseach of asthma and liver injury. Montelukast sodium also has an antioxidant effect in intestinal ischemia-reperfusion injury, and could reduce cardiac damage[1].
|
-
-
- HY-13315S
-
MK0476-d6 free acid
|
Isotope-Labeled Compounds
Leukotriene Receptor
|
Inflammation/Immunology
|
Montelukast-d6 is the deuterium labeled Montelukast (sodium). Montelukast sodium is a potent, selective and orally active antagonist of cysteinyl leukotriene receptor 1 (Cysltr1). Montelukast sodium can be used for the reseach of asthma and liver injury. Montelukast sodium also has an antioxidant effect in intestinal ischemia-reperfusion injury, and could reduce cardiac damage[1].
|
-
-
- HY-13628
-
LY293111; VML 295
|
Leukotriene Receptor
Apoptosis
|
Inflammation/Immunology
Cancer
|
Etalocib (LY293111), an orally active leukotriene B4 receptor antagonist, inhibits the binding of [ 3H]LTB4, with a Ki of 25 nM. Etalocib (LY293111) prevents LTB4-induced calcium mobilization with an lC50 of 20 nM. Etalocib (LY293111) induces apoptosis .
|
-
-
- HY-112741
-
|
Leukotriene Receptor
|
Inflammation/Immunology
|
SB-209247 is a selective, high affinity and orally active leukotriene B4 (LTB4) receptor antagonist with a Ki of 0.78 nM. SB-209247 blocks LTB4-induced Ca 2+ mobilization with an IC50 of 6.6 nM. SB-209247 shows a potent anti-inflammatory activity .
|
-
-
- HY-130138B
-
(5S,6R)-(11E)-DiHETE
|
Others
|
Inflammation/Immunology
|
(5S,6R)-DiHETEs is the isomer of (5S,6R)-DiHETE (HY-130138A). (5S,6R)-DiHETE can be recognized by leukotriene receptors (LTD4 receptors). (5S,6R)-DiHETE can induce guinea pig isolated ileum contraction with an EC50 of 1.3 μM, and this effect can be inhibited by LTD4 receptor antagonists .
|
-
-
- HY-16780
-
ONO-6950
|
Leukotriene Receptor
|
Inflammation/Immunology
|
Gemilukast is an orally active and potent dual cysteinyl leukotriene 1 and 2 receptors (CysLT1 and CysLT2) antagonist, with IC50s of 1.7, 25 nM for human CysLT1 and CysLT2, respectively. Gemilukast is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
-
- HY-112742
-
|
Leukotriene Receptor
|
Inflammation/Immunology
|
CP-195543 is a potent, selective and orally active leukotriene B4 (LTB4) receptor antagonist with IC50s of 6.8, 37.0 nM for human neutrophils and murine spleen membranes, respectively. CP-195543 blocks CD11b up-regulation. CP-195543 inhibits LTB4-mediated neutrophil infiltration .
|
-
-
- HY-13315
-
MK0476
|
Leukotriene Receptor
|
Inflammation/Immunology
|
Montelukast sodium (MK0476) is a potent, selective and orally active antagonist of cysteinyl leukotriene receptor 1 (CysLT1). Montelukast sodium can be used for the reseach of asthma and liver injury. Montelukast sodium also has an antioxidant effect in intestinal ischemia-reperfusion injury, and could reduce cardiac damage. Montelukast sodium decreases eosinophil infiltration into the asthmatic airways. Montelukast sodium can also be used for COVID-19 research .
|
-
-
- HY-13315A
-
MK0476 free base
|
Leukotriene Receptor
|
Inflammation/Immunology
|
Montelukast (MK0476 free base) is a potent, selective and orally active antagonist of cysteinyl leukotriene receptor 1 (CysLT1). Montelukast can be used for the reseach of asthma and liver injury. Montelukast also has an antioxidant effect in intestinal ischemia-reperfusion injury, and could reduce cardiac damage. Montelukast decreases eosinophil infiltration into the asthmatic airways. Montelukast can also be used for COVID-19 research .
|
-
-
- HY-13315B
-
MK0476 dicyclohexylamine
|
Leukotriene Receptor
|
Inflammation/Immunology
|
Montelukast (MK0476) dicyclohexylamine is a potent, selective and orally active antagonist of cysteinyl leukotriene receptor 1 (CysLT1). Montelukast dicyclohexylamine can be used for the reseach of asthma and liver injury. Montelukast dicyclohexylamine also has an antioxidant effect in intestinal ischemia-reperfusion injury, and could reduce cardiac damage. Montelukast dicyclohexylamine decreases eosinophil infiltration into the asthmatic airways. Montelukast dicyclohexylamine can also be used for COVID-19 research .
|
-
- HY-19989
-
L-660711
|
Leukotriene Receptor
LPL Receptor
|
Inflammation/Immunology
|
MK-571 (L-660711) is an orally active, potent and selective competitive leukotriene D4 (LTD4) receptor antagonist, with Ki values of 0.22 and 2.1 nM in guinea pig and human lung membranes, respectively. MK-571 is also a MRP4 and ABCC1 (MRP1) inhibitor. MK-571 inhibits constitutive and antigen-stimulated S1P (sphingosine-1-phosphate) release .
|
-
- HY-13315R
-
MK0476 (Standard)
|
Leukotriene Receptor
|
Inflammation/Immunology
|
Montelukast (sodium) (Standard) is the analytical standard of Montelukast (sodium). This product is intended for research and analytical applications. Montelukast sodium (MK0476) is a potent, selective and orally active antagonist of cysteinyl leukotriene receptor 1 (CysLT1). Montelukast sodium can be used for the reseach of asthma and liver injury. Montelukast sodium also has an antioxidant effect in intestinal ischemia-reperfusion injury, and could reduce cardiac damage. Montelukast sodium decreases eosinophil infiltration into the asthmatic airways. Montelukast sodium can also be used for COVID-19 research .
|
-
- HY-19989A
-
MK-571 sodium
Maximum Cited Publications
19 Publications Verification
L-660711 sodium
|
Leukotriene Receptor
LPL Receptor
|
Inflammation/Immunology
|
MK-571 (L-660711) sodium is an orally active, potent and selective competitive leukotriene D4 (LTD4) receptor antagonist, with Ki values of 0.22 and 2.1 nM in guinea pig and human lung membranes, respectively. MK-571 sodium is also a inhibitor of multidrug resistance-associated protein MRP4 (ABCC4) and ABCC1 (MRP1). MK-571 sodium inhibits constitutive and antigen-stimulated S1P (sphingosine-1-phosphate) release .
|
-
- HY-13315AR
-
|
Leukotriene Receptor
|
Inflammation/Immunology
|
Montelukast (Standard) is the analytical standard of Montelukast. This product is intended for research and analytical applications. Montelukast (MK0476 free base) is a potent, selective and orally active antagonist of cysteinyl leukotriene receptor 1 (CysLT1). Montelukast can be used for the reseach of asthma and liver injury. Montelukast also has an antioxidant effect in intestinal ischemia-reperfusion injury, and could reduce cardiac damage. Montelukast decreases eosinophil infiltration into the asthmatic airways. Montelukast can also be used for COVID-19 research .
|
-
- HY-163101
-
|
Platelet-activating Factor Receptor (PAFR)
Leukotriene Receptor
|
Inflammation/Immunology
|
CP-96021 is a potent and orally available leukotriene D4 (LTD4 Ki=34±5 μM) / platelet activating factor (PAF Ki=37±12 μM) receptor antagonist. CP-96021 has antagonist capable of simultaneously targeting two different inflammatory mediators, LTD4 and PAF. CP-96021 shows high specificity for α1, α2, β, dopamine-2, adenosine 1, 5-HT1, H1, muscarine, μ opioid, and GABA receptors, all expressing IC50 values greater than 10 μM. CP-96021 can be used to study the pathogenesis of many inflammatory diseases such as asthma .
|
-
- HY-161211
-
|
17β-HSD
iGluR
|
Metabolic Disease
|
HSD17B13-IN-7 (compound 1), a fluorophenol-containing compound, is a potent HSD17B13 inhibitor with IC50s of 0.18 μM and 0.25 μM β-estradiol and Leukotriene B4 as substrates, respectively. HSD17B13-IN-7 is a potent N-methyl-D-aspartate (NMDA) NR2B receptor antagonist. HSD17B13-IN-7 has the potential for non-alcoholic fatty liver disease research .
|
-
Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
Cat. No. |
Product Name |
Chemical Structure |
-
- HY-76511S
-
|
Verlukast-d6 is a deuterium labeled Verlukast. Verlukast is a potent, selective, and orally active antagonist of leukotriene receptor. Verlukast has the potential for the research of asthma[1].
|
-
-
- HY-17492S
-
|
Zafirlukast-d7 is the deuterium labeled Zafirlukast. Zafirlukast (ICI 204219) is a potent orally active leukotriene D4 (LTD4) receptor antagonist. Zafirlukast shows anti-asthmatic, anti-inflammatory and anti-bacterial effects[1][2].
|
-
-
- HY-17492S3
-
|
Zafirlukast-d6 is deuterated labeled Zafirlukast (HY-17492). Zafirlukast (ICI 204219) is a potent orally active leukotriene D4 (LTD4) receptor antagonist. Zafirlukast shows anti-asthmatic, anti-inflammatory and anti-bacterial effects.
|
-
-
- HY-17492S1
-
|
Zafirlukast- 13C,d3 is the 13C- and deuterium labeled Zafirlukast. Zafirlukast (ICI 204219) is a potent orally active leukotriene D4 (LTD4) receptor antagonist. Zafirlukast shows anti-asthmatic, anti-inflammatory and anti-bacterial effects.
|
-
-
- HY-17492S2
-
|
Zafirlukast- 13C,d6 is the 13C- and deuterium labeled Zafirlukast. Zafirlukast (ICI 204219) is a potent orally active leukotriene D4 (LTD4) receptor antagonist. Zafirlukast shows anti-asthmatic, anti-inflammatory and anti-bacterial effects.
|
-
-
- HY-13315S1
-
|
Montelukast-d6 (sodium) is the deuterium labeled Montelukast (sodium). Montelukast sodium is a potent, selective and orally active antagonist of cysteinyl leukotriene receptor 1 (Cysltr1). Montelukast sodium can be used for the reseach of asthma and liver injury. Montelukast sodium also has an antioxidant effect in intestinal ischemia-reperfusion injury, and could reduce cardiac damage[1].
|
-
-
- HY-13315S
-
|
Montelukast-d6 is the deuterium labeled Montelukast (sodium). Montelukast sodium is a potent, selective and orally active antagonist of cysteinyl leukotriene receptor 1 (Cysltr1). Montelukast sodium can be used for the reseach of asthma and liver injury. Montelukast sodium also has an antioxidant effect in intestinal ischemia-reperfusion injury, and could reduce cardiac damage[1].
|
-
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent: